ncip 2017 2017 supported by: institute of pharmacy, nirma university s. g. highway, chharodi,...

“Emerging Trends in Drug Discovery, Development and Molecular Targets for Cancer Research”

NCIP 2017

SUPPORTED BY:

Institute of Pharmacy, Nirma UniversityS. G. Highway, Chharodi, Ahmedabad – 382481, Gujarat, INDIA

Phone : 079 30642700, 079 30642716 • Website : http://www.ncip.in

ORGANIZED BY

nd2 National Conference of Institute of Pharmacy

January 24-25, 2017

OUR MOTTOFrom darkness, lead me to light

MISSION

Institute of Pharmacy emphasizes the all-round

development of its students. It aims at

producing not only good professionals, but also

good and worthy citizens of a great country,

aiding in its overall progress and development.

It endeavors to treat every student as an

individual, to recognize their potential and to

ensure that they receive the best preparation

and training for achieving their career

ambitions and life goals.

VISION

Shaping a better future for mankind

by developing effective and socially

responsible individuals and

organizations

QUALITY STATEMENT

To develop high quality professionals who reflect and demonstrate values that the University stands

for, through innovation and continuous improvement in facilitation of learning, research and

extension activities.

Dr. Harsh VardhanHon'ble Minister

Science & Technology andEarth Sciences,Govt. of India

nd2 National Conference of Institute of Pharmacy | NCIP 2017

Shri Vijay RupaniChief Minister of Gujarat

Institute of Pharmacy, Nirma University

Shri Nitinbhai PatelDy. Chief Minister of Gujarat


Shri Bhupendrasinh Chudasama

Hon'ble MinisterMinister,

Revenue, Education (Primary, secondary and

adult), Higher and Technical Education,

Legislative & Parliament Affairs.Government of Gujarat


Prof. D.P. Singh


Shri H.G. Koshiya


Dr. Karsanbhai K. PatelPresident

Nirma University

MESSAGE

I am pleased to know that Institute of Pharmacy, Nirma University is

organizing the 2nd National Conference of Institute of Pharmacy (NCIP –

2017) on “Emerging Trends in Drug Discovery, Development and

Molecular Targets for Cancer Research” from January 24-25, 2017.

The motive of the conference goes well with the present pharmaceutical

scenario. With the growing prevalence of the cancerous condition in India and

gloally, pharmaceutical industries are facing great challenge in meeting the

apt drugs to prevent its development as well as to maintain the quality of life

of the patients. Thus there is a desperate need to develop new and innovative

approaches for safe and efficacious drug development for cancer. The theme

of present conference addresses the burning issues pertaining to Innovation,

faced by the pharmaceutical research industry as well as health sector in India

and across the globe. Pharmaceutical companies must find a better way

through innovation in drug development, for the benefit of patients and to

increase their output of truly new drugs.

I heartily congratulate Institute of Pharmacy for organizing such event that

addresses hurdling factors in the path of innovation and drug development. It

will certainly help participants to solve the challenges in the drug discovery

process in cancer.

I heartily welcome all the invitees, delegates and researchers to the vibrant

land of Nirma University and wish for the grand success of this conference and

it is anticipated that Institute of Pharmacy will continue the tradition to explore

and come up with many such endeavors with enlightening themes in future.

Dr. Karshanbhai K Patel

President

Nirma University


Shri K. K. PatelVice-

Nirma UniversityPresident,

MESSAGE

I am gratified to welcome all invited guests and participants at Nirma

University for National Conference of Institute of Pharmacy (NCIP – 2017) on

“Emerging Trends in Drug Discovery, Development and Molecular Targets

for Cancer Research” from January 24-25, 2017.

Cancer is not one disease, it’s a plethora of disorders existing together. These

all diseases are different and unique diseases, which require different

approaches for treatment. Treatments that work for some cancers don’t work

for others and sometimes those treatments simply stop working. Research is

the best defense against cancer. Moreover, the nation’s investment in cancer

research is also increasing which is definitely helping the young researchers to

understand the various aspects of the disease and thus leading to innovative

methods to deal with its management.

In light of this, organization of such a conference will serve the purpose of

nurturing innovations in the field of cancer research and help in exchange of

research ideas amongst the budding scientists from academia and industries.

I heartily acknowledge the efforts of Institute of Pharmacy, Nirma University

for organizing such event that provides a common platform for all

stakeholders to put forward their views and opinions. I extend my best

compliments to Institute of Pharmacy for a grand success of this conference

and we hope that the Institute continues to fill the void in the pharmaceutical

sector by arranging many more conferences and workshops in future.

Shri K. K. Patel

Vice President

Nirma University


Dr. Anup K. SinghDirector GeneralNirma University

MESSAGE

I am delighted to hear that Institute of Pharmacy, Nirma University is organizing a

National Conference for the second time - National Conference of Institute of

Pharmacy (NCIP – 2017) on “Emerging Trends in Drug Discovery, Development

and Molecular Targets for Cancer Research” from January 24-25, 2017. It’s my honor

and privilege to welcome all the eminent speakers and delegates to the exquisite

campus of Nirma University.

Research in cancer involves several disciplines to work together leading to the

identification of the causes, targets and finally treatment for various types of cancer.

Safety and therapeutic efficacy of the intervention method is also an integral part of

the cancer research. The prevalence of cancers is increasing in less developed and

developing countries which poses us with a challenge to pursue our efforts in this area

for its efficient management. Such conferences will help spread the awareness as well

as a stage to discuss all the global isssues in cancer research and its challenges which

are varied across the globe.

I appreciate the efforts of Institute of Pharmacy for taking lead in fostering innovations

in drug discovery by organizing a conference on such sought after theme and to offer

common platform for the researchers from various parts of the country. I wish from the

bottom of my heart that this conference will serve as a medium to bring together

eminent personalities across the nation to share their experience in the field of drug

discovery and innovation in cancer.

I welcome all the dignitaries, delegates and participants at Nirma University for the

conference and wish Institute of Pharmacy to have a grand and successful event

Dr. Anup Singh

Director General,

Nirma University


We are heartily thankful to

Science and Engineering Research Board Department of Science and Technology

Indian Council of Medical Research

Defence R&D Organisation

CONTENTS

SR. TITLE PAGE

No. NO.

1 From the Desk of Organizers 2

2 About Nirma University, Institute of Pharmacy 3

3 Conference Advisory Committee 10

4 Organizing Committee – NCIP 2017 11

5 Students Task Force 13

6 Scientific Schedule 14

7 Chief Guest and Keynote Speaker 16

8 Plenary Lectures 19

9 Session Lectures 28


From the Desk of Organizers


On behalf of the Organizing Committee, we are delighted to invite all the delegates, invitees &

students to participate in the 2nd National Conference of Institute of Pharmacy (NCIP-2017) on

“Emerging Trends in Drug Discovery, Development and Molecular Targets for Cancer Research” held

during January 24-25, 2017.

The research data on cancer indicates strong need for discovery and development of new

therapeutic agents for prevention and cure of different types of cancer. The major problems with

chemotherapy used for treatment are resistance and side effects with currently available marketed

products. To address these issues, there is high need to develop compounds and use approaches

which are target specific and devoid of side effects as well as cost effective. It is predicted that

appropriate discovery & development for anticancer drugs in form of suitable dosage form may

show good efficacy and this research might decrease the death rate and improve the quality of life

of patients. In view of this, 2nd National Conference is organized on a theme “Emerging Trends in

Drug Discovery, Development and Molecular Targets for Cancer Research” which focus on

discussing and exploring opportunities of novel therapeutic strategies to combat cancer by active

involvement of academicians, scientists and clinicians from different disciplines. We look forward to

provide various interactive sessions for exchange of knowledge, ideas and discussions for providing

cutting edge research for identification of targets for diagnosis of cancer and its treatment. The

scientific program will focus on plenary lectures delivered by distinguished speakers, session

lectures by young scientists as well as poster sessions in various areas from all over India.

The organizing committee, under the valuable support and guidance of management of Nirma

University as well as advisory committee members will be able to give this shape of the conference

and ensure you great learning experience at conference. We acknowledge financial support

received from Department of Science & Technology (DST), Defense Research and Development

Organization (DRDO) and Indian Council of Medical Research (ICMR) as well as various industries. .

On behalf of the Local Organizing Committee, we look forward to welcoming you to Nirma

University, Ahmedabad for participating in conference and wish you all a good stay and memorable

time in this conference. We are looking forward for your dynamic support and valuable

cooperation to make this conference a grand success.

(Dr. Tejal Mehta) (Dr. Manjunath Ghate)

Organizing Secretary, NCIP-2017 Convener, NCIP-2017

Institute of Pharmacy, Nirma University Director, IP, NU

2

Nirma University was established by the initiative of the NERF. The University was established in the year 2003

as a statutory university under a special act passed by the Gujarat State Legislative Assembly. It is recognized

by the University Grants Commission (UGC) under Section 2 (f) of the UGC Act. The University is duly

accredited by National Assessment and Accreditation Council (NAAC) with ‘A’ grade. The University is a

member of Association of Indian Universities (AIU) and the Association of Commonwealth Universities (ACU).

Functioning under the aegis of NERF, the University consists of Faculty of Technology and Engineering,

Faculty of Management, Faculty of Pharmacy, Faculty of Law, Faculty of Science, Faculty of Architecture &

Planning, Faculty of Commerce and Faculty of Doctoral Studies and Research.

The University is identified with cutting edge research, robust academic programmes, quality teaching

learning process and over-all personality development interventions of its students. The 115 acres sprawling

state of art campus provides refreshing environment and stimulates intellectual growth and creativity.

The University has been awarded under the category of ‘Excellence in Technology for Education Delivery’

during the FICCI Education Awards 2015, as a part of the Eleventh FICCI Higher Education Summit 2015 held

during November 3-4, 2015 organized by FICCI in association with the Ministry of Human Resource

Development, Government of India.

In addition to above the University has also been accorded recognition as Scientific and Industrial Research

Organization by the Department of Scientific and Industrial Research, Department of Science and Technology,

Government of India in 2014.

ABOUT NIRMA UNIVERSITY

3


The Institute of Pharmacy was established with a view to promote excellence in pharmaceutical education

and to prepare young men and women to meet the challenges in the area of pharmaceutical industries,

education, research & development and marketing. Institute of Pharmacy is a model centre of excellence in

pharmacy, conducting various graduate, post graduate, full time and external doctoral and research programs

in pharmaceutical sciences. The institute is poised to face global challenges of the pharmaceutical industry

and education with the changed perspectives. The future pharmacists will be required to function,

communicate and work effectively in multidisciplinary teams. Institute of Pharmacy was established with a

view to promote excellence in Pharmaceutical education and to prepare generation next to meet the

challenges in the area of pharmaceutical industries, education, research and development as well as

marketing.

Institute of Pharmacy is ranked first in state and fifth in India among all pharmacy Institutes by MHRD, New

Delhi.

PROGRAMMES OFFERED BY THE INSTITUTE INCLUDE:

1. B. Pharm. (Eight semester programme)*

2. M. Pharm. (Four semester programme)* with specialization in:

• Pharmaceutical Technology & Bio-pharmaceutics

• Pharmacology

• Clinical Pharmacy

• Regulatory Affairs & Quality Assurance

• Medicinal Chemistry

3. Ph. D. in Pharmaceutical Sciences (Full time & External)**

*With Industrial Training, **With Course Work

CURRICULUM

The Institute has introduced an innovative curriculum befitting the needs of the day. It will be continuously

updated to integrate the rapidly occurring advances in the field of pharmaceutical sciences and drug

research. It is vital that universities and teachers recognize their responsibility in preparing not only

responsible members of healthcare team but also valuable members of the society, who must have top

quality scientific and professional skills, and an unquestionable sense of ethics. The content of course have

been carefully considered to ensure that they are relevant and up-to-date and special consideration has been

given to the application of knowledge, communication, language and patient care skills, healthcare system

organizations, the development of professional identity, critical thinking and lifelong learning.

4

ABOUT INSTITUTE OF PHARMACY


SPECIAL FEATURES

Institute of Pharmacy is a constituent unit of Nirma University which is recognized by University Grant

Commission (UGC) under section 2 (f) of the UGC Act. The B. Pharm. programme is approved by the

Pharmacy Council of India (PCI). Special features of our programmes are:

1. An innovative dynamic curriculum befitting the current needs of the profession.

2. More emphasis through audio visual and computer aided teaching.

3. More contact hours through regular theory classes and practicals in each subject and adequately

supervised training in practical classes.

4. Assessment on the basis of their day-to-day progress and input and improvised strict university

examination system for evaluation and grading.

5. Regular visits to the industries, CROs and R&D centers and a strong industry-academy interaction and a

regular visiting faculty from industries.

6. Constant mentoring to students by the faculty on one to one basis on career guidance for personal

development, identification of aptitudes and motivation in right direction.

7. Grooming and training of students with development of communication & soft skills and extensive

coaching for GPAT, TOEFL, GRE & other competitive exams.

8. Various Clubs like Cinema Club, Literature Club, Entrepreneurship Club, Music Lover’s Club, Arts & Craft

Club and Foreign Language Club for overall development of students.

9. Idea Lab, where students can discuss and work on innovative ideas.

THE CAMPUS

The Institute is situated in the Nirma University campus about 15 km. from Ahmedabad city, on the Sarkhej -

Gandhinagar Highway. It is spread over a 110-acre sprawling campus in picturesque surroundings providing a

refreshing environment, stimulating intellectual alertness and creativity. The campus has facilities for canteen,

bank, student store, playground, indoor games and gymnasium. The campus provides an ambience that

motivates students to grow.

5


The Institute building has modern amenities, with enough space and replenished with modernity and

grandeur. The postgraduate laboratories are independently developed for M. Pharm. and Ph. D. students.

Apart from this, the campus has sport facilities and the overall ambience is distinguishable by serenity, which

is conducive for intellectual pursuits

MAJOR FACILITIES AVAILABLE AT THE INSTITUTE:

CLASS ROOMS: The classrooms are air-conditioned, spacious, ventilated and equipped with multimedia and

audio visual equipment to facilitate effective learning. The classrooms are designed to provide maximum

interaction between the faculty and students.

COMPUTER CENTRE: The central computer facilities consist of 20+ servers and more than 1900 systems,

which are interconnected by fiber optic cables and 256 Mbps, leased line internet connectivity. Computing

facilities for students include a laboratory equipped with 31 computers for U.G. and 36 for P.G. to the

Windows XP and Local Area Network. The institute also houses a language laboratory to improvise the

students in languages & communication skills. The network also connects the faculty and staff for

information sharing and communication. The students have an easy access to the internet. The faculties are

also provided computer and internet facilities. The Institute has the Wi-Fi facility also. The central computer

facilities consist of 20+ servers and more than 1900 systems, which are interconnected by fiber optic cables

and 256 Mbps, leased line internet connectivity.

LEARNING RESOURCES CENTRE (LIBRARY):

At Institute of Pharmacy, it is a belief to facilitate production and dissemination of knowledge, information,

insights & intellect in all scientific communities. The Library plays a vital role in the collection development

and dissemination of scientific information and includes a wide range of volumes of different branches of

Pharmaceutical Sciences and allied subjects and also provides extensive access to leading Indian and

international research journals. The Library at Institute of Pharmacy houses more than 8,715 volumes of

books selectively chosen for reading and reference, 358 CDs, 1,654 Bound Volumes, 646 Project Reports

(B.Pharm), 395 Research Project Reports (M.Pharm), 39 PhD Thesis and subscribes about 26 printed national,

4 international periodicals, 16 magazines and 9 newspapers. Library is also providing Web access to 108 e-

journals: Science Direct: Pharmacology, Toxicology and Pharmaceutical Sciences Module (82), Bentham

Science Publisher (23) and Inventi E-Journals (2) and Pharmacological Review (1).

Online Resources:

Bentham Science Publisher is a major STM journal publisher of 92 online and print journals, 200 plus open

access journals, and related print/online book series, Bentham Science answers the informational needs of

the pharmaceutical, biomedical and medical research community. The connectivity to e-journal is through

IngentaConnect.com. Resources: 23 journals published by Bentham Science, Back Files: 2009, Access:

Unlimited

Science Direct is the web-based interface to the full-text database of Elsevier Science journals one of the

world's largest providers of scientific, technical and medical (STM) literature. The ScienceDirect offers a rich

electronic environment for research journals, bibliographic databases and reference works. We would get

unlimited and complete online access to 92 journals (Pharmacology, Toxicology and Pharmaceutical Science)

of Elsevier Science available in Science Direct database. Resource: 82 journals published by Elsevier Science,

Back-files: 1997 onwards, Simultaneous Access: Unlimited

6


AUTOMATION: The Library and Resource centre is fully automated with Open Source, user-friendly library

software KOHA that facilitates automated circulation (issue & return) of the books and location and

availability information of the books stocked in the library. Online Public Access Catalogue (OPAC) is also

available on the Internet for inquiring the status of the resources. Bar-coding system is in use to computerize

the bibliographic details of the resources.

SOPHISTICATED INSTRUMENT LABORATORY: The Institute houses modern analytical instruments like

Quaternary gradient GC system, FT-IR Florescence Spectrophotometer, UV-Spectrophotometer, HPLC,

Supercritical Fluid Chromatography and Extraction, HPTLC, PDA detector, MPLC, RAMAN Spectrophotometer

which provide analysis comprising elemental composition, chromatography, diffraction, particle/material

characteristics including various spectroscopes. The laboratory provides analytical support and intellectual

input to both in-house and externally funded R & D projects.

DRUG DISCOVERY LABORATORY: The Institute has a separate Drug Discovery Laboratory equipped with

necessary computational facilities. It possesses seven workstations (computers) with latest configurations. It

also possesses molecular modeling software like Sybyl X1.3 and Gold Suite 5.1. Students are trained on these

software for docking, pharmacophore modelling and QSAR studies etc.

MACHINE ROOM: Centralized machine room is equipped with rotary tablet machine, fluidized bed drier,

digital tensionmeter, texture analyzer, mini spray dryer, freeze dryer, automated dissolution apparatus, etc.

The laboratory provides facilities to carryout extensive research and consultancy for pharma Industries

NIRMA HERBAL WEALTH: A medicinal plants garden covering a total area of 3356.50 sq. meters has been

developed at the university campus. More than 150 Genus of various medicinal plants have been planted in

the garden. The plants garden provides a strong impetus for herbal drug research and for the training of our

P.G. & U.G. students ANIMAL HOUSE: Our Institute has state of the art animal house facility registered by

CPCSEA, Government of India. It is envisaged to provide preclinical testing in conformity with national and

international regulatory guidelines (Schedule Y, GLP and OECD). The animal house facilitates the availability

of healthy and homogeneous animals for U.G. and P.G. studies and for research / outsourced testing

7


8

RESEARCH LABORATORY: A fully dedicated research laboratory helps the faculty members to undertake

sponsored research projects as well as to carry out doctoral research work in various areas. The Institute

houses state-of-art analytical instruments like FT-IR, Fluorescence Spectrometer, Raman Spectrometer, UV-

Spectrophotometer, HPLC, GC, Texture Analyser, Automated Dissolution Apparatus, SFC & SFE, Microwave

Synthesizer, Biochemical Analyser, ELISA Reader etc.

ACHIEVEMENTS

A team of highly qualified and dedicated faculties are continuously skilled in latest methods of educational

technology and in their respective fields of specialization. Faculty members are actively involved in research,

consultancy and financially funded and sponsored projects.

Total 16 recognized Ph.D guides with more than 130 research scholars are actively working in the diversified

thrust areas of pharmaceutical sciences. Apart from presenting and publishing their work in reputed journals

and conferences, faculty members and students have won laurels for the Institute by publishing of books,

patenting their research work and by receiving many prestigious awards.

The Institute had received more than 3 crore rupees grant from various external funding agencies like GMDC

(Ahmedabad), DST, DBT, ICMR, AYUSH, GSBTM and GUJCOST. Institute has very high intellect faculty

members who are actively involved in research, consultancy, testing and are supported financially with

sponsored projects from different government as well as private organizations.


Many full time PhD research scholars have received the prestigious DST INSPIRE (Innovation in Science

Pursuit for Inspired Research) fellowship from the DST and CSIR, Government of India and from

Confederation of Indian Industries (CII).

Many M. Pharm students and research guides from the department of Medicinal Chemistry, Pharmaceutical

Technology & Bio-pharmaceutics, Pharmacology, Pharmacognosy and Pharmaceutical Analysis have received

national recognition for “R. V. Patel Competition for Best Thesis at Masters Programme” supported by DST,

Government of India and Troikaa Pharmaceuticals Ltd. Faculty members have been awarded with P. D. Sethi

awards, N. S. Dhalla Young Scientist award and APTI awards for publishing the best research papers and

presentations during symposiums and conferences. Faculty members have contributed in innovative

pharmaceutical research by solving web based challenges floated by the Innocentive. Inc. USA.

The graduate students have been awarded for securing the highest grade in B.Pharm Examinations and

many students performed well to achieve All India rank in GPAT and secured admissions at reputed institutes

like IITs, NIPER and other PG centres of India and also abroad. The post graduate students have been placed

at reputed academic institutions and industries of India.

Different departments of Institute have received support from government organizations like ICMR, DST,

AICTE, ISTE, GUJCOST, DBT, DRDO and CSIR in organizing various workshops, conferences and symposia of

national and international level on recent advances in pharmaceutical sciences.

RESEARCH COLLABORATION WITH RESEARCH INSTITUTES/ UNIVERSITY:

• Plovdiv University, Bulgaria

• B. V. Patel PERD centre, Ahmedabad

• Cadila Pharmaceuticals Clinical Research and Pharmacology Centre, Dholka

• Intas Pharmaceuticals Ltd., Ahmedabad

• Piramal Pharmaceutical Development Services Ltd., Ahmedabad

• Green Chem Ltd., Bangalore

• Ayurlab Herbals, Vadodara

• Beiersdorf AG (Nivea), Germany

9


CONFERENCE ADVISORY COMMITTEE

Conference Advisory Committee is constituted to have constant guidance from eminent persons from the

field of academia and pharmaceutical industries, for sustaining and enhancing teaching as well as research

activities at Institute of Pharmacy, Nirma University. Committee comprising members of National repute is

constituted with the following:

• Dr. Ajay Khopade, Sr. Vice President, Sun Pharma Advanced Research Centre, Vadodaa

• Dr. Mukul Jain, Senior Vice President at Zydus Research Centre, Ahmedabad

• Dr. Rakesh Rawal, Sr. Scientific Officer, The Gujarat Cancer & Research Institute, Ahmedabad

• Dr. Sunil Kumar, Scientist G and Director I/c, National Institute of Occupational Health, Ahmedabad

• Dr. M. T. Chhabaria, Principal, L. M. College of Pharmacy, Navrangpura, Ahmedabad

• Dr. Kiran Kalia, Director, National Institute of Pharmaceutical Education and Research-Ahmedabad

• Dr. Chirag Desai, Vedant Hospital, Ahmedabad

10


CHIEF PATRON

VARIOUS COMMITTEES

CONVENER

Scientific

Committee

Prof. Jigna Shah

Dr. Snehal Patel

Dr. Renuka Mishra

Dr. Nagja Tripathi

Dr. Dipal Gandhi

Dr. Palak Parikh

Mr. Mukesh Patel

Mr. Shreyas Bhuva

Registration

Committee

Dr. Hardik Bhatt

Dr. Vivek Vyas

Ms. Jigisha Patel

Mr. Hasmukhbhai Rathod

Ms. Jaya Dabhi

11

ORGANIZING COMMITTEE

Shri K. K. Patel

Vice-President, Nirma University

Dr. Anup K. Singh

Director General, Nirma University

Prof. Tejal Mehta

Professor and Head, Dept. of Pharmaceutics, Institute of Pharmacy

Nirma University

Prof. Manjunath D. Ghate

Director

Institute of Pharmacy

Nirma University

ORGANIZING SECRETARY


Finance Committee

Dr. Bhumika D. Patel

Mr. Dinesh Patel

Mr. Devendrabhai Vaghela

Stage and Venue Management

Prof. Priti Mehta

Dr. Bhoomika M. Patel

Mr. Manish Patel

Transport, Accommodation &

Logistics

Dr. Mayur Patel

Dr. Mohit Shah

Mr. Nityanandan Murlidhar

Mr. Jignesh Patel

Mr. Shailesh Patel

Hospitality & Memento

Dr. Charmy Kothari

Dr. Jigar Shah

Ms. Shilpa Patel

Printing Committee

Dr. Shital Butani

Dr. Shraddha Bhadada

Press and Publicity

Dr. Shital Panchal

Catering

Mr. Nrupesh Patel

Mr. Rohitbhai Patel

Sponsorship

Dr. Niyati Acharya

Mr. Tushar Patel

Website Management

Dr. Dhaivat Parikh

Mr. Virendra Goswami

Correspondence

Dr. Jignasha Savjani

Ms. Pooja Pandey

12


STUDENTS TASK FORCE

Scientific Committee

Ms. Krishna Gajjar

Ms. Priyal Barai

Ms. Anita Bakrania

Mr. Chetan Dhal

Ms. Shruti Rawal

Mr. Piyush Gediya

Ms. Parmi Patel

Ms. Khushali Parekh

Registration Committee

Ms. Manali Prajapat

Ms. Prutha Patel

Ms. Misari Patel

Ms. Viral Patel

Ms. Keerti Vishwakarma

Finance Committee

Mr. Devang Shelat

Stage and Venue Management

Ms. Komal Chaudhary

Ms. Dhara Bhayani

Ms. Sushma Rawat

Ms. Nisith Raval

Mr. Krunal Prajapati

Printing Committee

Mr. Amarjit Rajput

Ms. Neha Shah

Ms. Tejal Rawal

Mr. Bharat Patel

Transport & Accommodation

Mr. Ankit Borisa

Mr. Udit Chaube

Mr. Chintan Pansara

Mr. Namdev Dhas

Mr. Vivek Bora

Mr. Vishal Chavda

Hospitality & Memento

Mr. Nimitt Chokshi

Ms. Mital Patel

Ms. Mansi Patel

Mr. Manan Shah

Mr. Vimal Patel

Ms. Angana Shastri

Ms. Niyati Mehta

Press and Publicity

Mr. Abhishek Jha

Catering

Mr. Nikum Sitwala

Sponsorship

Ms. Tripti Halder

13


14

SCIENTIFIC SCHEDULE

Theme: Emerging Trends in Drug Discovery, Development

and Molecular Targets for Cancer Research

1:.15 pm to 2:15 pm Lunch Break

Chair Person: Dr. Prabhudas Patel, Deputy Director, GCRI

3.45 pm to 4.00 pm Tea- Coffee and Networking

4:00 pm to 6:00 pm Poster Session (All Tracks)

Venue: Institute of Pharmacy

12:30 pm to 1:15 pm Prof. Santosh Kar

Professor, School of Biotechnology

KIIT University, Bhubaneswar, Odissa Quality of Life of Cancer Patients

Plenary Lecture-1

Formulation to Improve the

2:15 pm to 3:00 pm Dr. Narshimnha P. Argade

Sr. Principal Scientist and Professor

Division of Organic Chemistry,

NCL (CSIR), Pune

3.00 pm to 3:45 pm Dr. Kiran Marthak Plenary Lecture-3

Director, Head Global Clinical Regulatory Scenario for Oncology

Development, Lambda Therapeutic Products in India

Research Ltd., Ahmedabad

Plenary Lecture-2

Science of Synthesis and Medicines

Venue: Auditorium, Institute of Management, Nirma University, Ahmedabad

th th24 - 25 January, 2017

thDAY 1: 24 JANUARY, 2017 (TUESDAY)

9:15 am to 10:15 am Registration and Breakfast

10:15 am to 11:30 am Inaugural session

Chief Guest: Dr. Shilin Shukla

Professor Emeritus & Former Director, GCRI, Ahmedabad

11.30 am to 12:30 pm Keynote Address

Dr. Harish Padh

Ex. Vice Chancellor, Sardar Patel University, Vallabh Vidyanagar

Chair Person: Dr. C. J. Shishoo, Former Director, B. V. Patel PERD Centre


15


thDAY 2: 25 JANUARY 2017 (WEDNESDAY)

9:00 to 9:30 am Registration and Breakfast

Chair Person: Dr. M. C. Gohel, Research Director, Anand Pharmacy College

11.00 to 11.15 am Tea Break

Chair Person: Dr. Rakesh Raval, Sr. Scientist, GCRI

3:15 pm to 4:00 pm Valedictory Function

4:00 pm onwards Tea- Coffee and Networking

12:15 pm to 1:00 pm Lunch Break

Chair Person: Dr. Bhaswat Chakraborty, Sr. VP & Chair, Cadila Pharma. Ltd.

Chair Person: Dr. Manish Nivsarkar, Director, B. V. Patel PERD Centre

9:30 to 10:15 am Dr. Ajay Khopade

(Non-Orals),

Advanced Research Co. Ltd., Vadodara

10:15 to 11:00 am Dr. Manoj Kumar Bhat Plenary Lecture-5

Scientist G, National Centre for

Cell Science (NCCS), Pune of Membrane Cholesterol

Plenary Lecture-4

Vice president- R&D, Formulation A Novel Platform Nanotechnology

Development Sun Pharma for Anticancer Drug Delivery

Cancer Chemotherapy: Involvement

11:15 am to

12:15 pm Assistant Professor, Dept. of Cell Role of FADD and cFLIPL in Regulation

Biology, IIAR, Gandhinagar of Programmed Cell Death Signaling:

Molecular Target for Cancer Therapy

Associate Professor, Bharati Vidyapeeth’s Clinical Relevant Herb-drug Interaction

College of Pharmacy, Mumbai in Oncology- Case Studies to Analysis

Dr. Deepak Kumar Session Speaker- 3

Assistant Professor, Dept. of Medicinal Design Synthesis Anticancer and

& Pharma. Chemistry, School of Docking Studies of Some Novel

Pharmacy, Sharda University, U.P Catechin and Quinazolinone Derivatives

Dr. Chandramani Pathak Session Speaker- 1

Mrs. Vinita Khanvilkar Session Speaker- 2

1:00 pm to 1:45 pm Dr. Chirag Desai

Medical Oncologist, Vedanta Institute Challenges in Oncology Drug Development

of Medical Sciences, Ahmedabad in Molecular Arena

1.45 pm to 2:30 pm Dr. R. Srinivasan Plenary Lecture-7

Chief Scientist & Head, Mass & Analytical Characterization of drug metabolites

Division, Indian Institute of Chemical and degradation products using

Technology (IICTH), & Dean, LC-ESI-MS/MS

NIPER, Hyderabad

Plenary Lecture-6

2:30 pm to 3:15 pm Dr. Mukul Jain Sr. Vice President & Head of Nonclinical Discovery & Development of a Novel and Potent

Research & Development, ZRC, Ahmedabad Poly (ADP-ribose) Polymerase (PARP) & Tankyrase

Inhibitor for Management of Solid Tumors

Plenary Lecture-8

16

Chief Guest and Keynote Speaker

Dr. Shilin ShuklaProfessor Emeritus,

Medical Oncology-GCRI, Ahmedabad

Former, Hon. Director, GCRI, Ahmedabad

BIODATA

Dr. Shilin Shukla is Professor Emeritus, Medical Oncology-GCRI, Ahmedabad. He is former Hon. Director,

GCRI, Ahmedabad and Professor, Medical and Haem-Oncology, GCRI & BJ Medical College. He is Member,

Court, Central Gujarat University, Gandhinagar Since 2013. He is an author and Editor of Gujarati Vishwakosh,

Encyclopaedia-Medical Section, Since 1985 and also Hon. Consultant, Gujarati Lexicon (Dictionary): Gandhiji's

Gujarat Vidyapith since 1998. He was Editor-in-Chief for Journal of Indian Society of Med. & Paediatric

Oncology (1999-02) and Consultant Editor, Journal of Indian Society of Med. & Paediatric Oncology (1995-

98). He was Member of Core Committee for Translated Books, University Granth Nirman Board (2013). He has

headed various professional organizations like Indian Society of Medical and Paediatric Oncology, Gujarat

Physician Association, Ahmedabad Physician Association, Ahmedabad Medical Association and Indian

Association of Cancer Research-Gujarat Chapter. He is Managing Trustee, Navjivan High School Trust Since

1990. He has delivered several Orations, Key Note addresses and prestigious lectures across the country

17

CHIEF GUEST


Dr. Harish PadhFormer Vice-Chancellor

Sardar Patel University, Vallabh Vidyanagar

BIODATA

Dr. Harish Padh is Former Vice-Chancellor, Sardar Patel University, Vallabh Vidyanagar. Dr.Padh obtained his

Ph.D. in Biochemistry from University of Delhi in 1978. From 1978 to 1995 for 17 years, he has developed his

academic career in USA at places like Temple University, Philadelphia, University of Chicago, Chicago and

Northwestern University, Evanston, Illinois. He was Assistant Director and Associate Professor at Northwestern

University for Biotechnology. In 1996, he returned to India and joined as Professor of Biochemistry at M. S.

University of Baroda and later he joined as Director, B. V. Patel Pharmaceutical Education and Research

Development (PERD) Centre in Ahmedabad. In 2007, he also took responsibility as Project Director for NIPER,

a Government of India's Institution at Ahmedabad. Later, he joined Sardar Patel University as Vice-Chancellor

in 2010. His area of research is Cell and Molecular Biology as applied to Health and Pharmaceutical Sciences.

Dr. Padh has more than 150 research publications in reputed journals. He has organized and attended many

scientific symposia / meetings in India and abroad. He is the member in several Editorial Boards and

Societies. In addition, Dr. Padh is the Advisor to Government of Gujarat for pharmaceuticals and

biotechnology matters. He is a recent recipient of B-School Excellence Award given jointly by UTV-

Bloomberg, STAR group of Industries; and The Name in Science Award by European Science Congress and

European Business Assembly, UK. He is member of Governing Council of Gujarat Forensic Science University

Gandhinagar, Central University of Gujarat-Gandhinagar, Association of Indian Universities-New Delhi,

Member, Indian Institute of Science, Bangalore.

18

KEY NOTE SPEAKER


19

Plenary Lectures

Formulations to Improve the Quality of Life of Cancer

Patients

Prof. Santosh K KarProfessor

School of Biotechnology, KIIT University

Bhubaneshwar, Odish, India.

BIODATA

Prof Santosh K Kar is Professor at School of Biotechnology, KIIT University, Bhubaneshwar, Odisha. Prof. Kar

completed his PhD from IIT, Kanpur and M. Sc from Utkal University. Dr. Kar was visiting scientist at MRC

Laboratory for Molecular Biology, Cambridge, England as well as International Laboratory for Research on

Animal Diseases (ILRAD), Nairobi, Kenya. He has worked in prestigious institutes including National Institute

of Immunology, New Delhi, Regional Medical Research Centre, Bhubaneswar and Centre for Biotechnology,

Jawaharlal Nehru University, New Delhi, TIFR, Mumbai as Research fellow, Assistant Professor in Department

of Biological Sciences, BITS, Pilani

ABSTRACT

Cancer is a disease of the chromosome and alterations in the genome leads to abnormal functioning of the

cancer cells. Therefore, treatment of cancer should aim at prevention of this chromosomal alteration and if

possible reversal of the damage when a daughter cell is generated. In a cancer patient, there is suppression

of the immune response and cells like monocytes and macrophages which are meant to control the

progression of tumors actually promote them. Recent studies have shown that in response to invasion by a

cancer cell, both T-effector cells and T-regulatory cells are generated but, unfortunately the generated

regulatory T-cells migrate more rapidly towards the tumor and these regulatory T-cells then block the action

of effector T-cells, thus preventing them from attacking and destroying the cancer cells.

Besides suppressing the immune system, cancer cells migrate from the primary site of infection to different

sites and establish themselves by a process known as metastasis. For these they take the help of the

inflammatory response of the immune system which helps in the synthesis of cell adhesion molecules.

Therefore any process, which will appropriately stimulate the immune system and prevent cell migration may

help in controlling cancer. After migration to a new site, the cancer cells grow into a tumor by a process

called angiogenesis which supplies the blood to the cells present in the tumor. Any molecule which prevents

angiogenesis will help in killing a tumor cell.

Chemotherapy is extensively used for treatment of various types of cancer in humans. all chemotherapeutic

agents are toxic and they induce inflammatory responses in the patients. Control of inflammatory response

induced by the chemotherapeutic agents during the treatment of cancer would be very beneficial to improve

the quality of life of cancer patients.

Therefore, an immunomodulator and anti-inflammatory molecule like curcumin helps in controlling cancer

progression by appropriately modulating the body's immune responses and tightly regulating and enhancing

healthy control over cellular replication by altering various cell signaling pathways. Curcumin is also

immensely beneficial because it does not affect healthy tissues but selectively induces apoptosis in rapidly

dividing cancer cells. Also, it prevents angiogenesis and kills tumors by depriving them of the vital blood

supply and further, prevents metastasis by blocking molecules that otherwise promote cancer cell migration.

Andrographolide is another molecule that shows very good hepatoprotective and anti-angiogenic properties.

Thus, combining curcumin and andrographolide as a formulation to prevent tumor cell growth and migration

would be very beneficial. We will discuss about our work using such a formulation in improving the quality of

life of cancer patients.

20


Science of Synthesis and Medicines

Dr. A. Narshinha P. ArgadeSenior Principal Scientist

Division of Organic Chemistry

National Chemical Laboratory (CSIR)

Pune, India

BIODATA

Dr. A. Narshinha is Senior principal scientist and professor AcSIR at National Chemical Laboratory, Pune. He

has undertaken training with eminent chemists namely Dr. V. Balasubramaniyan (Doctoral work, 1984-89), Dr.

S. Rajappa (RA, 1990-92) and Prof. Kenji Mori (Post-doctoral work, 1993-94) with national and international

scholarships. He was Visiting Associate Professor at University of Tokyo, Tokyo, Japan. He has thirty two years

research experience in basic and applied organic chemistry with 117 publications in national and

international journals. He is a reviewer for many journals including Journal of Organic Chemistry and Organic

Letters. His areas of interest in Organic Synthesis include Heterocycles, Steroids, Pheromones, Bioactive

Natural Products, Drugs, Drug Intermediates, Asymmetric Synthesis and Combinatorial Chemistry. He has

successfully completed several national, international, industry and DST sponsored projects. He has received

Prof. V. V. Kogekar First Rank Award, The Chemical Research Society of India Young Scientist Award, Professor

R. C. Shah Memorial Lecture Award, Professor N. S. Narasimhan Trust Endowment Prize for Research in

Chemistry, NCL Research Foundation Scientist of the Year Award.

ABSTRACT

Total synthesis of bioactive natural products leading to essential medicines is the priority area in science.

Development of new synthetic stratagems for the collective total synthesis of different classes of natural

products is a challenging task of contemporary interest. A brief introduction to the science of synthesis and

concise account on synthesis of selected bioactive natural products, medicines and some useful products

with special emphasis on the involved new reactions and strategic steps will be presented.

21


Regulatory Scenario for Oncology Products in India

Dr. Kiran Marthak Director, Head Global Clinical Development,

Lambda Therapeutic Research Ltd., Ahmedabad,

Gujarat, India.

BIODATA

Dr. Kiran V. Marthak is Director, Lambda Therapeutic Research since September 2011. Previously he served as

Corporate Medical Director at Veeda Oncology. Dr. Marthak served as Vice President of Clinical Research &

Medical Affairs for Ranbaxy Laboratories Limited until August 2004. He has vast experience in Phase I clinical

research working for Novartis for 13 years pioneering phase I studies in India. He has also initiated clinical

trials for USFDA submission and data management while working with Pfizer as Vice President Clinical

Research. He worked with Ranbaxy as Vice President Clinical Research and with German Remedies as Medical

Director. Dr. Marthak is a pioneer and a very senior clinical trials professional with over 25 years of active

participation in clinical research. He is President - Association of Medical Advisors of Pharmaceutical Industry

and an Executive Committee Member - International Federation of Association of Pharmaceutical Physicians

as well as being a Board Member for designing the modules for Academy of Clinical Research, Chief

organizer of the International conference of Clinical Research held by CII-New Delhi in the year 2002 and a

member of the Faculty for Pharmaceutical medicine - University of London, Fellow member - American

college of Chest Physician, and Fellow member - Royal Society of Medicine. Dr. Marthak is an accomplished

speaker having delivered lectures on clinical research in various National and International Forums including

being invited by Harvard business school to deliver a lecture on Scope of Clinical Research in India and by

Stanley business school to talk on CROs and Clinical Research in India. He is a Member of the Medical

Committee- Indian Drug Manufacturer's Association, a Member-India Task Force- DIA, USA, a Founder

Member- Clinical Research Institute, India and a Member of the Delegation- Gujarat Government, Vibrant

Gujarat. He is associated with regulatory authorities like US FDA, UK MHRA, China SFDA, South Africa MCC,

MHCW, and DCGI in India. He has several publications to his credit. He has an M D Medicine awarded from

Dr. Grant Medical College and is also a Business Management Degree holder.

ABSTRACT

There are regulatory requirement for Drug Discovery as well as Clinical Development of any New Molecule

including for Oncology area. The various requirements will be discussed. There should be awareness about all

the Regulatory requirements of major countries. It will help in shortening the development time

22


A Novel Platform Nanotechnology for Anticancer

Drug Delivery

Dr. Ajay KhopadeVice President-R&D, Formulation Development (Non-Orals)

Sun Pharma Advanced Research Co. Ltd. (SPARCL)

Vadodara

BIODATA

Dr. Ajay Khopade is Vice President R&D (Formulation Development) and heads Non-oral division at Sun

Pharma Advanced Research Co. Ltd. (SPARCL), a pharmaceutical research and drug discovery company

separated out from a leading speciality Sun Pharmaceutical Industries Limited. With over 18 years of

experience in pharmaceutical product development, in his current role as Vice President-R&D, Dr.Khopade is

responsible for development of SPARC’s innovative and differentiating drug product portfolio and product

life-cycle management through strategic innovation planning & road mapping. Dr. Khopade has extensive

development experience across multiple therapeutic areas in novel parenteral dosage forms and has

participated as CMC expert in the submission of number of INDs, NDAs and technology evaluation for in-

licensing opportunities. Currently, he is leading a team of scientists supporting development of niche

products and platform technologies. He is an inventor of a platform nanotechnology in the field of Oncology

(Nanotecton®), Ophthalmics (GFR® and SMM®) and Depot injections protected by various IPs globally with

over a dozen patents. Dr. Khopade has been a Humboldt post-doctoral fellow at Max Plank institute of

Colloids and Interfaces, Germany. He holds a Ph.D. degree in Pharmaceutical Sciences from the University of

Sagar, MP, India. His areas of interest are physical chemistry of drug delivery system design

ABSTRACT

Aqueous solubility of most of the cytotoxic anticancer drug makes it difficult to formulate and administer

drug to the patient. Large quantities of toxic solvents are used to solve this problem, e.g. approximately 500

mg of Cremophor is used to solubilize 6 mg Paclitaxel in the product Taxol which amounts to about 24-25g

per therapeutic dose of 175mg/m2. This limits the ability to give cytotoxic drug at higher doses. It may also

require concurrent medication, special infusion sets and on-line filters etc. Another problem is that the

solubilized drug lack specificity to the tumor. Nanotechnology solves many of the listed formulation and

administration problems. It also alters the pharmacokinetics of the drug and allows preferential accumulation

in tumor though EPR effect. The presentation shall cover:

• Novel strategies for anticancer drug delivery

• Novel assembly of the drug into soft nanoparticles

• Understanding the therapeutic benefits of nano-structure assembly

• Optimizing PK profiles

• Maximising safety & efficacy of anticancer therapies

• Extending platform to multiple drug candidates

Take Home Message:

Differentiation through drug delivery technology

23


Cancer Chemotherapy: Involvement of Membrane

Cholesterol

Dr. Manoj Kumar Bhat, PhD

Scientist G, National Centre for Cell Science, Pune,

Maharashtra, India.

BIODATA

Dr. Manoj Kumar Bhat is Scientist 'G' at National Centre for Cell Science, Pune. Dr. Bhat has worked with

various reputed institutes in various capacities such as Research Associate at Institute of Human Virology,

University of Maryland and Visiting Fellow at National Cancer Institute, NIH, Bethesda, USA. Previously, he

worked in the capacity of Senior research fellow at Department of Biochemistry, University of Mysore. He has

received number of fellowships from Indian Council of Medical Research, University Grants Commission,

Fogarty International Research, National Academy of Sciences. He has been nominated for DST-IUSSTF

Khorana Program Technology Transfer Course and is elected member, Molecular Immunology Forum. Dr. Bhat

has sixty publications in peer-reviewed journals, one book chapter, two patents filed and two patent

published, one technology transfer to industry to his credit. He is a reviewer for national and international

grant applications and peer-reviewed journals.

ABSTRACT

The significance of discovering new targets, pathways and strategies for therapeutic intervention in cancer is

extremely important. Over many decades researchers, by utilizing cell culture studies, animal research and

human trials have identified hundreds of potential chemotherapeutic agents and their specific targets for the

treatment of various cancers. In-spite of all these advances, the need for exploring new treatment approaches

exists. For almost all the chemotherapeutic drugs, plasma membrane is the first entry point; thereafter these

agents are located to the site of action. Plasma membrane contains nanometer-size dynamic micro domains

enriched in cholesterol, sphingolipids, and gangliosides called 'lipid rafts'. These micro domain structures are

very important regulators of influx or efflux of chemotherapeutic drugs. Cholesterol present on micro

domains play essential role in the regulation of membrane integrity, fluidity and ion channel activity.

Depletion of membrane cholesterol disrupts the integrity of lipid raft and enhances the permeability of ions

and small non-electrolytes. Interestingly, reactivation of lipid biosynthesis is frequently observed in cancer

tissue and therefore it is likely that targeting membrane cholesterol may have significant impact on

therapeutic response. The presentation covers the significance of cholesterol on the response of cancer cells

to chemotherapeutic agents.

24


Challenges in Oncology Drug Development in

Molecular Arena

Dr. Chirag DesaiMedical Oncologist, Vedanta Institute of Medical Sciences,

Ahmedabad, Gujarat, India.

BIODATA

Dr. Chirag Desai completed MD in 1991 and DM in Medical Oncology in 1993 from Ahmedabad, India. He

was Faculty in Medical Oncology at Cancer Hospital in Ahmedabad from the year 1993-1998. Later on, he

worked as Project Manager in Indian office of a large international CRO and then as National Co-ordinator

and Medical advisor for oncology trials. He is actively working in oncology practice for last seventeen years.

He is Consultant Oncologist and one of the Directors of Hemato-Oncology Clinic, Vedanta Institute of

Medical Sciences, Ahmedabad. He was associated with Vibgyor Scientific Research Pvt. Ltd, Ahmedabad and

Apollo Hospital, Gandhinagar. He is Executive committee member of Indian Society of Medical and Pediatric

Oncology (ISMPO), Indian Cooperative Oncology Network (ICON), Gujarat Society of Head and Neck Cancer

(GSHNO). He is member of various professional bodies. He is advisor and consultant for Indian and

Multinational Pharmaceuticals/CROs. Dr. Desai is involved in 31 clinical trials as Principal Investigator and 30

international clinical trials as co-investigator.

ABSTRACT

The unfolding of human genome towards the end of last millennium has opened up the avenues of

molecular medicine. All the sub-specialties of medicine, particularly oncology has been immensely benefited.

Understanding the molecular basis of oncogenesis and progression of tumor has led to development of

molecularly targeted treatment and we have started seeing the improvement in the outcome of various

cancers due to systematically developed drugs.

This has also raised several questions about the validation of the targets, whether the target is also expressed

by normal tissue, whether so called targeted drugs often miss the target and so on.

Drug development has been even more challenging in recent time. In the presentation, identification and

validation of molecular targets, development of the drugs directed to these targets and selection of end

points and regulatory requirements will be discussed

25


Characterization of drug metabolites and degradation

products using LC-ESI-MS/MS

Dr. Srinivas, Ragampeta Chief Scientist & Head, Mass & Analytical Division, Indian Institute of Chemical

Technology (IICTH), Dean and course coordinator (PA), NIPER (H),

Punjab, India.

BIODATA

Dr. R. Srinivas obtained his B.Sc. and M.Sc (chemistry, 1979) from Osmania University and Ph.D. from I.I.T.

Chennai in June 1985. He joined the mass spectrometry division, IICT, as a scientist in December 1984. During

1989-1991, on his selection as a DAAD fellow, he went to Germany to carry out his post doctoral research at

Technical University Berlin; Visiting scientist at Institute of Organic Chemistry, TU, Berlin and Univ of Wurzberg

for 3 months in 1999; Visited VG Analytical, Manchester, U.K for a training program on advanced applications

of mass spectrometry for two weeks in 1995. He has 2000 citations and has contributed a book chapter on

“Neutralization- Reionisation Mass Spectrometry” in the book titled “Introduction to Mass Spectrometry”

published by Indian Society for Mass Spectrometry, BARC, Mumbai, India. He contributed to fundamental

and applied research in organic and biological mass spectrometry apart from supervising mass spec services

for IICT projects, industry, academia and government agencies. Received “Eminent Mass Spectrometrist “

award in the year 2003 from Indian Society for Mass Spectrometry, BARC, Mumbai; One of his papers (J. Am.

Chem. Soc. 113, 5970 (1991) was adjudged by ' “The Scientist (USA)” as a hot paper in 1992; Fellow of

A.P./Telangana Akademi of Sciences; Fellow of Royal Society of Chemistry (London). One of his papers was

adjudged by “The Scientist (USA)” as a hot paper in 1992. He is advisory board member of National Authority

of Chemical weapons convention, New Delhi and life member of various professional bodies.

ABSTRACT

Over the years, stress studies of drugs have been recognized as an essential part of the drug development

process. These studies are used to investigate the intrinsic stability of the drugs and provide the foundation

for the development of a selective stability indicating assay method (SIAM). Stress testing is also useful for

the formulation and packaging development, shelf-life determination and designing of manufacturing

processes. As per regulatory guideline stress degradation studies and structural characterization should be

carried out to establish degradation pathways of the drug, which is essential from both quality and

safety point of view.

Drug metabolism and pharmacokinetic (DMPK) study is another important aspect of early drug discovery

process to optimize new chemical entities. These metabolism studies involve metabolic stability, cytochrome

P450 (CYP) induction or inhibition and metabolite identification. Metabolite identification is the most

important part of drug metabolism. Identification of reactive metabolites is essential to avoid the toxicity and

helps to modify the structure. Liquid chromatography electrospray ionization tandem mass spectrometry (LC-

MS/MS, MSn) combined with H/D exchange experiments is the most popular analytical technique for

identification and structural characterization drug degradation products and metabolites. This lecture will

focus on some of our recent studies at IICT on stress studies and in vivo metabolic investigation of drugs

including some anti cancer molecules which have been carried out using liquid chromatography-electrospray

ionization tandem mass spectrometry (LC-ESI-MS/MS).

26


Discovery & development of a novel and potent poly

(ADP-ribose) polymerase (PARP) and tankyrase

inhibitor for management of solid tumors

Dr. Mukul R. JainSenior Vice President & Head, Nonclinical Research & Development

Zydus Research Centre, Sarkhej-Bavla NH 8A, Moraiya, Ahmedabad – 382213,

Gujarat, India.

BIODATA

Dr. Mukul Jain is a Senior Vice President, and Head of Nonclinical Research & Development at Zydus Research

Centre (ZRC) at Ahmedabad. Since July, 2000 he has been associated with Zydus Cadila group and is involved

in discovery & development of New Chemical Entities in different therapeutic areas. He was the key person

responsible for discovery & development of Saroglitazar / LipaglynTM, the first new drug from Indian

Pharmaceutical Industry in recent time and also the first 'Glitazar' class drug approved anywhere in the world

for human use. Besides Saroglitazar, his group has contributed to development of 13 other NCEs that

received IND approvals in India or abroad. He has also contributed to nonclinical development of 13

recombinant biologics and 12 vaccines of Zydus Cadila.

ABSTRACT

Poly (ADP-ribose) polymerase (PARP) are nuclear enzymes activated by DNA strand breaks and are involved

in recruitment of DNA repair proteins at the sites of damage, whereas tankyrases are key regulators of cellular

processes such as telomere pathway and Wnt signaling. Studies have shown that PARP and TNK inhibition

have significant anti-tumor effect in several types of cancers including BRCA -ve breast cancers. Zydus has

discovered a novel PARP-TNKS inhibitor named ZYTP1 using a series of in vitro and in vivo assays. ZYTP1 was

found to be a potent PARP and TNKS inhibitor in cell free assay. In vitro cell killing potency of ZYTP1 was

tested in a panel of cell lines including BRCA -ve cells. In a BRCA -ve cell line, MDA-MB436, ZYTP1 alone

showed good cell kill potency. ZYTP1 was found to potentiate methyl methane sulfone (MMS)-mediated cell

killing activity in various cell lines. The pharmacokinetic profile of ZYTP1 was determined in preclinical species

including rodents and non-rodents. ZYTP1 demonstrated good Caco2 permeability and oral bioavailability.

ZYTP1 was also tested in different xenograft models in combination with temozolomide (TMZ) and cisplatin.

ZYTP1 showed efficacy in colon, prostate, ovarian and lung cancer xenograft models in combination with

temozolomide (TMZ) or cisplatin. In comparative efficacy studies in lung cancer xenograft model, ZYTP1

showed superior efficacy than olaparib an approved PARP inhibitor drug. In colon tumor xenograft model,

ZYTP1 inhibited PARylation. ZYTP1 showed efficacy as a single agent in a BRCA -ve breast cancer xenograft

model. In a repeat dose once-daily oral toxicity study in rats and dogs, it was found to have good safety

margins. In conclusion, ZYTP1 is a novel molecule that shows potential for development as a treatment for

various types of solid tumors.

27


Session Lectures

28

Role of FADD and cFLIPL in regulation of programmed

cell death signaling: Molecular target for cancer

therapy

Dr. Chandramani PathakAssistant Professor, Dept. of Cell Biology, IIAR, Gandhinagar, Gujarat, India.

BIODATA

Dr. Chandramani Pathak is currently serving as Assistant Professor at Department of Cell Biology, Indian

Institute of Advanced Research, IAR University, Gandhinagar. He has completed his Ph.D in Biochemistry from

Jiwaji University, Gwalior. He has received various awards and fellowships like Elsevier Pharmacological

Reports Reviewer award, 2016, DST Young Scientist, 2011, DBT Young Investigator, 2010, Dr. D.S. Kothari, UGC

Postdoctoral Fellowship, 2008 and ICMR-SRF, 2004. He has received several research grants worth Rs. 1.8

crores from various agencies like DBT, DST and GSBTM. He has 16 full length research papers in international

peer reviewed journals. He is a recognized Ph.D guide at University of IAR and University of Pune.

ABSTRACT

Fas-associated death domain protein (FADD) and cFLIP (Cellular FLICE-like inhibitory protein) both are pivotal

components for apoptotic and non-apoptotic signaling. FADD is an adaptor protein that provides docking

site for pro-caspase-8/ 10 and cFLIP for regulation downstream death inducing signaling complex (DISC)

associated signaling of programmed cell death Dysregulated expression of FADD and cFLIP is associated with

resistance to apoptosis in cancer cells. Thus, FADD and cFLIP both are important component to determine the

fate of cell death or survival. Indeed, cancer cells escape apopsis by activating the core anti-apoptotic NF-κB

signaling and associated gene products such as cFLIPL, cIAPs and Bcl-2 to promote cell proliferation. In

addition during cytotoxic stress, cancer cells known to induce autophagy with the aid of cFLIP and Bcl-2 to

transiently reduce apoptotic burden. Our recent reports revealed that induced expression of the FADD

alleviates the expression of cFLIPL and induces apoptosis, independent of death receptor stimulation.

However, the underlying molecular mechanism of FADD in regulation of cFLIP and NF-κB signaling to balance

apoptosis and autophagy remains elusive. We found that, selective knockdown of cFLIPL augments

autophagic stress in the cells with altered interaction between autophagic protein Beclin-1 with Bcl-2.

Notably, knockdown of cFLIPL facilitates JNK1 activation accompanied with p53 dependent ubiquitination of

Beclin-1. Moreover, we explored a novel mechanism of FADD in regulation of cFLIP, cIAP2 and Bcl-2. We

found that, induced expression of FADD firmly interacts with procaspase-8 and precludes cFLIPL at DISC. In

addition, FADD was also found to promote JNK1 mediated activation of E3 ubiquitin ligase ITCH to degrade

cFLIPL that leads to commencement of apoptosis. Altogether, we explored that cFLIPL provides a line of

defence for cell survival in cancer to resist cytotoxic stress, but FADD has enormous potential to regulate the

expression of cFLIPL to determine the fate of cells. Therefore, FADD and cFLIPL both are important molecular

target for intervention of cancer therapy.

29


Clinically Relevant Herb-Drug Interactions in Oncology:

Case Studies to Analysis

Mrs Vineeta Vivek KhanvillarAssociate Professor,

Bharati Vidyapeeth's College of Pharmacy, Mumbai, India,

BIODATA

Mrs. Vineeta Khanvillar is currently working with Bharati Vidyapeeth's College of Pharmacy, Belapur, Mumbai

as an Associate Professor in Pharmaceutical Analysis. She has eighteen years of teaching experience. She is

M. Pharm Research Guide from the University of Mumbai in the faculty of Pharmaceutical Analysis and

Quality Assurance. She has guided thirteen M.Pharm students in various research areas and three students

are currently working under guidance. Her research areas include Analytical and Bioanalytical Method

Development and Validation, Standardization of various Ayurvedic and Herbal formulations and herb-drug

interactions. She has worked on three minor research projects sponsored by the University of Mumbai. She

has published twenty nine research papers and four review articles in various national and international

journals. She has presented number of posters in national and international conferences. Mrs. Khanvillar is a

member of professional societies like Association of Pharmaceutical Teachers of India and Chromatographic

Society of India.

ABSTRACT

Cancer is characterized by uncontrolled cellular growth, local tissue invasion and distant metastasis. An

increasing number of cancer patients are using complementary and alternative medicines. The common

misconception of “natural means safe” is one of the reasons why patients do not inform their physicians or

pharmacists about their herbal product use. Concurrent use of two different treatment modalities carries the

risk of drug interactions amongst the two therapies.

Drug interactions in oncology are of particular importance owing to the narrow therapeutic indices and

inherent toxicity of anticancer agents. A large number of herbal remedies are used by cancer patients for

treating cancer and/or reducing the toxicities of chemotherapeutic drugs. Some herbal medicines have

shown potentially beneficial effect on cancer progression and may ameliorate chemotherapy induced

toxicities. On the other hand severe toxic interactions of anticancer drugs with certain herbs are also reported

in the literature. The scientific session will review some potential herb-drug interactions related to anticancer

drugs reported in literature supported with case studies.

Despite the plethora of information regarding herbal products, documented instances of herb-drug

interactions are sparse and it is indeed need of the hour to identify such interactions with sensitive analytical

methods to avoid or minimize toxic drug interactions. The session will briefly take an account of analytical

approaches used to identify possible herb-drug interactions.

30


Design Synthesis Anticancer and Docking Studies of

some Novel Catechin and Quninazolinone Derivatives

Dr. Deepak KumarAssistant Professor, Department of Pharmaceutical Chemistry,

School of Pharmacy, Sharda University, Greater Noida, Delhi, India.

BIODATA

Dr. Deepak Kumar is currently working as Assistant Professor at Sharda University, Noida, India. Dr. Kumar

received his Doctor of Philosophy degree from South Korea under prestigious Brain Korea 21Plus fellowship.

He did his M. Pharm from Sikkim Central University, Sikkim and B. Pharm from Uttar Pradesh Technical

University, Lucknow. He has published more than 30 research paper in SCI journals of international reputes.

He has presented and attended his research work in several National and International conference at U.K,

China, Hong Kong and Korea. He has more than 200 citation and h and i-10 index 9. Dr. Kumar has delivered

lectures as keynote speaker in National and International conferences. Recently, he has been awarded with

young investigator Award 2016 for his research work. His area of interest includes Medicinal Chemistry and

Drug Discovery; Bioorganic Chemistry; Drug Delivery; Nanomedicine. His current interest includes Design and

synthesis diversified bioactive small molecules and their application in chemical biology and medicinal

chemistry.

ABSTRACT

A series of catechin derivatives were designed, synthesized and fully characterized by analytical data. The

compounds was screened against various cancer lines such as human alveolar adenocarcinoma epithelial cell

line (A549), human breast adenocarcinoma cell line (MDA-MB-231), human prostate cancer cell line (DU145)

and human hepatocellular liver carcinoma cell line (HepG2) using MTT assay. Most of the synthesized

compounds exhibited significant activities, among which, four compounds showed potent and broad

spectrum anti-proliferative effects. Molecular docking showed good binding affinity of compound at the

active site of IGF-1R complementing the biological activity for anticancer activity. Beside this we synthesized a

series of quinazolinone and benzimidazole derivatives and characterized by IR, NMR, mass spectra and

elemental analyses. The synthesized compounds were evaluated for their in vitro cytotoxic activity against

cervical cancer (HeLa), breast cancer (MCF-7), leukemia cells (HL-60) and hepatocellular carcinoma (HepG2)

cell lines. The derivative 1e which displayed potent activities against MCF-7 3 times than that of the standard

drug Cisplatin. The IC50 value of 4e againstHepG2 is twofold lesser than Cisplatin whereas the IC50 value

against HeLa and HL-60 was equivalent to Cisplatin. Furthermore the histopathological studies confirm to be

non toxic.

31


About Ahmedabad

32

Ahmedabad, one of the liveliest cities in India and one of the major industrial centers in India, had often

been called the ‘Manchester of the East’. Ahmedabad is the largest city in Gujarat with a population of

about 5 million. The city has developed itself into a leading industrial centre and has become economic

capital of Gujarat. Ahmedabad offers something to celebrate all year round that ranges from celebrations

of ‘Deepawali’, ‘Navratri’ and ‘Kite Festival’. The city has many places to visit, like Science City, Akshardham

Temple, Gandhi Ashram, Adalaj Vav (step well) etc. The weather of Ahmedabad is very pleasant during the

month of January.


Acknowledgements

33

• Partron Sponsor : Aculife Healthcare Ltd. (Formerly Nirlife), Ahmedabad

• Conference Kit Bag Sponsor : BAN Labs Ltd., Rajkot

• Silver Sponsor : Fincecure Pharmaceuticals, Ahmedabad

• Anton Paar, Gurgaon

• Mehta Sales Corporate, Ahmedabad

• Lab Intelligence Appliances (LIA), Ahmedabad

• Biokrom, Ahmedabad

• Piyush Chemicals, Ahmedabad

• Guru Sales Corporation, Ahmedabad

• Durga Scientific ltd., Vadodara

• Omni Instrument Services, Ahmedabad

• Shyam Medico, Ahmedabad

• Starcoin Enterprise, Ahmedabad

• Surekh Educational, Ahmedabad


Media Partners:

34

Institute of Pharmacy, Nirma University,

Sarkhej - Gandhinagar Highway, Chharodi,Ahmedabad – 382481

Phone No: 079 30642700, 079 30642716 • Fax No.: 02717 241916

E mail: [email protected] • Website: http://www.ncip.in

ncip 2017 2017 supported by: institute of pharmacy, nirma university s. g. highway, chharodi,...

Documents